Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
JNJ News
On Tuesday, Johnson & Johnson (NYSE:JNJ) reported a third-quarter 2025 adjusted earnings of $2.80 per share, up 15.7% year over year, beating the consensus of $...
Argus analyst David Toung raised the firm’s price target on Johnson & Johnson to $210 from $185 and keeps a Buy rating on the shares. The firm cites the company...
Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor mod...
Analyst ratings
50%
of 26 ratingsMore JNJ News
Bank of America Securities analyst Tim Anderson has reiterated their neutral stance on JNJ stock, giving a Hold rating today. Elevate Your Investing Strategy: T...
Johnson & Johnson has a very healthy financial profile and growth prospects. Johnson & Johnson (JNJ -0.02%) is one of the world's best dividend stocks. The hea...
Johnson & Johnson ( (JNJ) ) has released its Q3 earnings. Here is a breakdown of the information Johnson & Johnson presented to its investors. Elevate Your Inv...
Johnson & Johnson ((JNJ)) has held its Q3 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRank...
Johnson & Johnson reported higher-than-expected third-quarter results and raised its 2025 earnings guidance, now projecting annual product revenue between US$93...
Analyst Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson and increased the price target to $222.00 from $185.00. Elevate Your Investing...
Earnings Call Insights Johnson & Johnson outlines orthopaedics spin-off and targets 5.7% reported sales growth for 2025 amid accelerating MedTech and Innovative...
